Neoadjuvant	B:C0392943
FOLFOX	I:C0392943
chemotherapy	I:C0392943
combined	O
with	O
radiotherapy	O
followed	O
by	O
radical	O
resection	I:C0728940
in	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

Neoadjuvant	O
FOLFOX	I:C0392943
chemotherapy	I:C0392943
combined	O
with	O
radiotherapy	B:C1522449
followed	O
by	O
radical	O
resection	I:C0728940
in	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

Neoadjuvant	O
FOLFOX	I:C0392943
chemotherapy	I:C0392943
combined	O
with	O
radiotherapy	O
followed	O
by	O
radical	B:C0728940
resection	I:C0728940
in	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

Neoadjuvant	O
FOLFOX	I:C0392943
chemotherapy	I:C0392943
combined	O
with	O
radiotherapy	O
followed	O
by	O
radical	O
resection	I:C0728940
in	O
patients	O
with	O
locally	B:C0007102
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

Patients	O
with	O
locally	B:C0007102
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
(	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
)	O
have	O
a	O
relatively	O
poor	O
prognosis	O
despite	O
radical	O
resection	I:C0728940
and	O
adjuvant	O
chemotherapy	I:C0085533
.	O

Patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
(	O
locally	B:C0007102
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
)	O
have	O
a	O
relatively	O
poor	O
prognosis	O
despite	O
radical	O
resection	I:C0728940
and	O
adjuvant	O
chemotherapy	I:C0085533
.	O

Patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
(	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
)	O
have	O
a	O
relatively	O
poor	O
prognosis	B:C0033325
despite	O
radical	O
resection	I:C0728940
and	O
adjuvant	O
chemotherapy	I:C0085533
.	O

Patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
(	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
)	O
have	O
a	O
relatively	O
poor	O
prognosis	O
despite	O
radical	B:C0728940
resection	I:C0728940
and	O
adjuvant	O
chemotherapy	I:C0085533
.	O

Patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
(	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
)	O
have	O
a	O
relatively	O
poor	O
prognosis	O
despite	O
radical	O
resection	I:C0728940
and	O
adjuvant	B:C0085533
chemotherapy	I:C0085533
.	O

This	O
study	B:C2603343
investigated	O
the	O
treatment	O
efficacy	O
and	O
toxicity	O
of	O
neoadjuvant	O
chemoradiotherapy	I:C0436307
in	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

This	O
study	O
investigated	O
the	O
treatment	O
efficacy	O
and	O
toxicity	B:C0600688
of	O
neoadjuvant	O
chemoradiotherapy	I:C0436307
in	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

This	O
study	O
investigated	O
the	O
treatment	O
efficacy	O
and	O
toxicity	O
of	O
neoadjuvant	B:C0436307
chemoradiotherapy	I:C0436307
in	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

This	O
study	O
investigated	O
the	O
treatment	O
efficacy	O
and	O
toxicity	O
of	O
neoadjuvant	O
chemoradiotherapy	I:C0436307
in	O
patients	O
with	O
locally	B:C0007102
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

We	O
retrospectively	O
reviewed	O
36	O
patients	O
with	O
locally	B:C0007102
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
preoperatively	O
treated	O
with	I:C0332293
chemotherapy	O
and	O
radiotherapy	O
.	O

We	O
retrospectively	O
reviewed	O
36	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
preoperatively	O
treated	B:C0332293
with	I:C0332293
chemotherapy	O
and	O
radiotherapy	O
.	O

We	O
retrospectively	O
reviewed	O
36	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
preoperatively	O
treated	O
with	I:C0332293
chemotherapy	B:C3665472
and	O
radiotherapy	O
.	O

We	O
retrospectively	O
reviewed	O
36	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
preoperatively	O
treated	O
with	I:C0332293
chemotherapy	O
and	O
radiotherapy	B:C1522449
.	O

Patients	O
were	O
administered	O
chemoradiotherapy	B:C0436307
,	O
which	O
comprised	O
radiotherapy	O
and	O
neoadjuvant	O
chemotherapy	I:C3665472
involving	O
a	O
5	O
-	I:C0016360
fluorouracil	I:C0016360
,	O
leucovorin	O
,	O
and	O
oxaliplatin	O
regimen	O
every	O
2	O
weeks	O
.	O

Patients	O
were	O
administered	O
chemoradiotherapy	O
,	O
which	O
comprised	O
radiotherapy	B:C1522449
and	O
neoadjuvant	O
chemotherapy	I:C3665472
involving	O
a	O
5	O
-	I:C0016360
fluorouracil	I:C0016360
,	O
leucovorin	O
,	O
and	O
oxaliplatin	O
regimen	O
every	O
2	O
weeks	O
.	O

Patients	O
were	O
administered	O
chemoradiotherapy	O
,	O
which	O
comprised	O
radiotherapy	O
and	O
neoadjuvant	B:C3665472
chemotherapy	I:C3665472
involving	O
a	O
5	O
-	I:C0016360
fluorouracil	I:C0016360
,	O
leucovorin	O
,	O
and	O
oxaliplatin	O
regimen	O
every	O
2	O
weeks	O
.	O

Patients	O
were	O
administered	O
chemoradiotherapy	O
,	O
which	O
comprised	O
radiotherapy	O
and	O
neoadjuvant	O
chemotherapy	I:C3665472
involving	O
a	O
5	B:C0016360
-	I:C0016360
fluorouracil	I:C0016360
,	O
leucovorin	O
,	O
and	O
oxaliplatin	O
regimen	O
every	O
2	O
weeks	O
.	O

Patients	O
were	O
administered	O
chemoradiotherapy	O
,	O
which	O
comprised	O
radiotherapy	O
and	O
neoadjuvant	O
chemotherapy	I:C3665472
involving	O
a	O
5	O
-	I:C0016360
fluorouracil	I:C0016360
,	O
leucovorin	B:C0023413
,	O
and	O
oxaliplatin	O
regimen	O
every	O
2	O
weeks	O
.	O

Patients	O
were	O
administered	O
chemoradiotherapy	O
,	O
which	O
comprised	O
radiotherapy	O
and	O
neoadjuvant	O
chemotherapy	I:C3665472
involving	O
a	O
5	O
-	I:C0016360
fluorouracil	I:C0016360
,	O
leucovorin	O
,	O
and	O
oxaliplatin	B:C0069717
regimen	O
every	O
2	O
weeks	O
.	O

Patients	O
were	O
administered	O
chemoradiotherapy	O
,	O
which	O
comprised	O
radiotherapy	O
and	O
neoadjuvant	O
chemotherapy	I:C3665472
involving	O
a	O
5	O
-	I:C0016360
fluorouracil	I:C0016360
,	O
leucovorin	O
,	O
and	O
oxaliplatin	O
regimen	B:C0040808
every	O
2	O
weeks	O
.	O

Seven	O
(	O
19.4	O
%	O
)	O
patients	O
developed	O
grade	O
3	O
or	O
4	O
adverse	B:C0877248
events	I:C0877248
during	O
neoadjuvant	O
concurrent	O
chemoradiotherapy	O
.	O

Seven	O
(	O
19.4	O
%	O
)	O
patients	O
developed	O
grade	O
3	O
or	O
4	O
adverse	O
events	I:C0877248
during	O
neoadjuvant	B:C0600558
concurrent	O
chemoradiotherapy	O
.	O

Seven	O
(	O
19.4	O
%	O
)	O
patients	O
developed	O
grade	O
3	O
or	O
4	O
adverse	O
events	I:C0877248
during	O
neoadjuvant	O
concurrent	O
chemoradiotherapy	B:C0436307
.	O

Pathologic	B:C4054230
responses	I:C4054230
were	O
not	O
evaluated	O
in	O
two	O
patients	O
who	O
did	O
not	O
undergo	O
radical	O
resection	I:C0728940
.	O

Pathologic	O
responses	I:C4054230
were	O
not	O
evaluated	O
in	O
two	O
patients	O
who	O
did	O
not	O
undergo	O
radical	B:C0728940
resection	I:C0728940
.	O

Of	O
the	O
34	O
patients	O
who	O
underwent	O
surgery	B:C0543467
,	O
nine	O
(	O
26.4	O
%	O
)	O
achieved	O
a	O
pathologic	O
complete	I:C4050242
response	I:C4050242
(	O
pathologic	O
complete	I:C4050242
response	I:C4050242
)	O
.	O

Of	O
the	O
34	O
patients	O
who	O
underwent	O
surgery	O
,	O
nine	O
(	O
26.4	O
%	O
)	O
achieved	O
a	O
pathologic	B:C4050242
complete	I:C4050242
response	I:C4050242
(	O
pathologic	O
complete	I:C4050242
response	I:C4050242
)	O
.	O

Of	O
the	O
34	O
patients	O
who	O
underwent	O
surgery	O
,	O
nine	O
(	O
26.4	O
%	O
)	O
achieved	O
a	O
pathologic	O
complete	I:C4050242
response	I:C4050242
(	O
pathologic	B:C4050242
complete	I:C4050242
response	I:C4050242
)	O
.	O

Our	O
results	O
demonstrated	O
that	O
neoadjuvant	B:C0436307
chemoradiotherapy	I:C0436307
is	O
feasible	O
and	O
safe	O
.	O

A	O
prominent	O
pathologic	B:C4050242
complete	I:C4050242
response	I:C4050242
rate	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
suggests	O
that	O
the	O
multimodality	O
therapy	O
might	O
be	O
a	O
treatment	O
option	O
for	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

A	O
prominent	O
pathologic	O
complete	I:C4050242
response	I:C4050242
rate	O
with	O
an	O
acceptable	O
toxicity	B:C0600688
profile	O
suggests	O
that	O
the	O
multimodality	O
therapy	O
might	O
be	O
a	O
treatment	O
option	O
for	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

A	O
prominent	O
pathologic	O
complete	I:C4050242
response	I:C4050242
rate	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
suggests	O
that	O
the	O
multimodality	O
therapy	O
might	O
be	O
a	O
treatment	B:C0087111
option	O
for	O
patients	O
with	O
locally	O
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

A	O
prominent	O
pathologic	O
complete	I:C4050242
response	I:C4050242
rate	O
with	O
an	O
acceptable	O
toxicity	O
profile	O
suggests	O
that	O
the	O
multimodality	O
therapy	O
might	O
be	O
a	O
treatment	O
option	O
for	O
patients	O
with	O
locally	B:C0007102
advanced	I:C0007102
colon	I:C0007102
cancer	I:C0007102
.	O

